

In re Application of
----------------------

Harvey A. Schwertner et al

Application Number

10/016.826 November 9, 2001

BILIRUBIN TESTS AS RISK PREDICTORS FOR CANCER MORTALITY, RHEUMATOID ARTHRITIS, GILBERT'S SYNDROME AND ALL-CAUSE MORTALITY

Docket Number (Optional)

AFD 490

Group Art Unit Examiner 1743 Maureen Wallenhorst

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.

The requested extension and appropriate non-small-entity fee are as follows (check time period desired):

- One month (37 CFR 1.17(a)(1))
  - 110.00
- Two months (37 CFR 1.17(a)(2))

410.00 930.00

Three months (37 CFR 1.17(a)(3)) Four months (37 CFR 1.17(a)(4))

1,450.00

Five months (37 CFR 1.17(a)(5))

- 1.970.00
- Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$ \_\_\_\_\_\_ .
- A check in the amount of the fee is enclosed.
- Payment by credit card. Form PTO-2038 is attached.
- The Commissioner has already been authorized to charge fees in this application to a Deposit Account.
- The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number AF 01-0465. I have enclosed a duplicate copy of this sheet.

I am the

applicant/inventor

assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

attorney or agent of record.

attorney or agent under 37 CFR 1.34(a).

Registration number if acting under 37 CFR 1.34(a).

Fredric L. Sinder, Reg. No. 28,475

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required. See below.

*	Total of	form(s) are subm	itted

00000045 010465 11/05/2003 JADDD1